ClinicalTrials.gg
RecruitingNCT07226076Updated Feb 4, 2026

Methadone in TKA for Post-op Pain and Opioid Reduction

A Phase 3 interventional study of Methadone Hydrochloride in Post Operative Pain, sponsored by Medical University of South Carolina. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by Medical University of South Carolina · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 37 studies testing methadone in Pain, Postoperative — 8 open to participants now, 8 under way, 3 of them phase 3. Methadone · Pain, Postoperative.

Planned enrollment
5th of 37
162 · median 75
Started
2026
with 4 others
Phase 3
7 of 37
3 open now
Registered
34th of 37
by date
Lead sponsor
2 of 37
Medical University of South Carolina

Among the 37 studies testing methadone in Pain, Postoperative, this one is the 5th largest by planned enrollment, is one of 5 that started in 2026, is one of 7 in phase 3, and was the 34th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

8 of the 37 studies testing methadone in Pain, Postoperative are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methadone

Methadone: first FDA approval 1947 (DOLOPHINE HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies testing methadone in Pain, Postoperative, or all of them as a file.
02

Study summary

This randomized, double-blind controlled trial investigates whether intraoperative IV methadone (0.15 mg/kg based on ideal body weight) reduces acute postoperative pain and opioid consumption in patients undergoing elective total knee arthroplasty under spinal anesthesia with mepivacaine.

03

Conditions studied

  • Post Operative Pain

Browse trials for

Keywords

  • post-operative pain
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ages 18-75 years of age
  • Undergoing elective primary total knee arthroplasty with mepivacaine in the spinal anesthesia

Exclusion criteria

Exclusion

  • Allergy to methadone or mepivacaine
  • Severe liver disease defined as Child's Pugh Class C
  • End stage renal disease requiring dialysis
  • Known diagnosis of prolonged syndrome
  • Currently pregnant
  • Unable to provide written,
  • Non-English speaking
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
162 participants (estimated)

Study arms

  • Active comparator
    Methadone

    Patients will intraoperatively receive methadone 0.15mg/kg IV, based on ideal body weight.

    Drug: Methadone Hydrochloride

  • No intervention
    No Methadone

    Patients will NOT receive methadone.

Interventions

  • DrugMethadoneStudies of MethadoneMethadone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will intraoperatively be administered methadone 0.15mg/kg IV, based on ideal body weight.

06

What researchers measure

Primary outcomes

  1. Patient reported pain in the recovery unit after surgery

    Patient reported pain on a Visual Analog Scale (VAS) from 0-100mm at approximately 30-60 minutes after arriving to the recovery unit after surgery. A lower pain score means a better outcome.

    Time frame: up to 24 hours after surgery ends

Secondary outcomes

  1. Opioid Consumption in the recovery unit

    Opioid consumption measured in oral morphine milligram equivalents (MMEs) while the patient is in the PACU (Post-Anesthesia Recovery Unit).

    Time frame: PACU Arrival until PACU Discharge up to 30 days

  2. Time to first opioid rescue dose

    Measured from the PACU arrival time, to the time the first opioid rescue dose is given while in the PACU.

    Time frame: up to 24 hours after surgery ends

  3. Pain scores

    Visual Analog Score (VAS) 0-100mm reporting pain at rest, and with movement. A lower pain score means a better outcome.

    Time frame: PACU, 24 hours, 48 hours, and 72 hours post-operatively.

  4. Postoperative nausea and/or vomiting

    Incidence of postoperative nausea and/or vomiting after surgery as reported by the patient.

    Time frame: PACU through 72 hours post-operatively

  5. Quality of Recovery

    Change in quality of recovery score from baseline to 24-hours post-operatively measured using the Quality of Recovery 15 Assessment (QoR-15). This assessment is scored 0-150, with a higher score indicating a better quality of recovery. Each of the 15 questions is on an 11-point numerical rating scale from 0-10, and the selections are added together to result in the total score.

    Time frame: up to 24-hours post-operatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

Of 124 non-industry phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 11 months is below that.

Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2025
First posted
Nov 10, 2025
StartActual
Jan 8, 2026
Primary completionEst.
Dec 28, 2026
CompletionEst.
Jan 15, 2027
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07226076
Responsible party
William Barrett (Assistant Professor-Faculty, Medical University of South Carolina) — Principal investigator
First posted
Nov 10, 2025
Start date
Jan 8, 2026
Primary completion
Dec 28, 2026 (estimated)
Completion
Jan 15, 2027 (estimated)
Last update
Feb 4, 2026

Study contacts

Haley Nitchie, MHA
Contact
nitchie@musc.edu
843-792-1869
William Barrett, M.D.
principal investigator · Medical University of South Carolina

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methadone

Start the discussion